Skip to main content
Top
Published in: BMC Infectious Diseases 1/2010

Open Access 01-12-2010 | Research article

Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: A retrospective, population-based study

Authors: Leonardo Emberti Gialloreti, Monica Merito, Patrizio Pezzotti, Luigi Naldi, Antonio Gatti, Maud Beillat, Laurence Serradell, Rafaelle di Marzo, Antonio Volpi

Published in: BMC Infectious Diseases | Issue 1/2010

Login to get access

Abstract

Background

Data on the epidemiology and cost of herpes zoster (HZ) and post-herpetic neuralgia (PHN) in Italy are limited. This retrospective, population-based study was designed to determine the incidence of HZ and the proportion developing PHN in Italy and the associated medical resource utilisation and costs. It focused primarily on immunocompetent patients aged ≥50 years who would be eligible for preventive vaccination.

Method

Data were extracted from a primary-care database and national hospital-discharge records covering four major regions in Italy for 2003-2005. Cases of HZ and PHN (1 and 3 months' duration; PHN1 and PHN3) were identified by ICD9-CM codes and, additionally for PHN, prescription of neuropathic pain medication.

Results

Over 3 years, 5675 incident cases of HZ were documented in adults, of which 3620 occurred in immunocompetent patients aged ≥50 years (incidence of 6.31 per 1000 person-years [95% CI: 6.01-6.62]). Of the immunocompetent patients aged ≥50 years with HZ, 9.4% (95% CI: 8.2-10.7) and 7.2% (95% CI: 6.2-8.2) developed PHN1 and PHN3, respectively. Increasing age, female sex, and being immunologically compromised conferred increased risk for both HZ and PHN. Overall, about 1.3% of HZ and almost 2% of PHN cases required inpatient care, with 16.9% of all HZ-related hospitalisations due specifically to PHN. In patients aged ≥50 years, mean stay was 7.8 ± 5.4 days for HZ and 10.2 ± 8.6 days for PHN, and direct costs associated with inpatient care were more than 20 times outpatient costs per HZ case (mean ± SD: €2592 ± €1313 vs. €122.68 ± €97.51) and over 5 times more per episode of PHN (mean ± SD: €2806 ± €2641 vs. €446.10 ± €442.97). Total annual costs were €41.2 million, of which €28.2 million were direct costs and €13.0 million indirect costs.

Conclusions

This study, the largest to date on the epidemiology and economic impact of HZ and PHN in Italy, confirms the considerable disease and economic burden posed by HZ. As HZ and PHN disproportionately affect the elderly, without intervention this problem is likely to grow as the proportion of elderly in the Italian population continues to increase.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bowsher D: The lifetime occurrence of herpes zoster and prevalence of postherpetic neuralgia: a retrospective survey in an elderly population. Eur J Pain. 1999, 3: 335-342. 10.1016/S1090-3801(99)90015-0.CrossRefPubMed Bowsher D: The lifetime occurrence of herpes zoster and prevalence of postherpetic neuralgia: a retrospective survey in an elderly population. Eur J Pain. 1999, 3: 335-342. 10.1016/S1090-3801(99)90015-0.CrossRefPubMed
2.
go back to reference Edmunds WJ, Brisson M, Rose JD: The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine. 2001, 19: 3076-3090. 10.1016/S0264-410X(01)00044-5.CrossRefPubMed Edmunds WJ, Brisson M, Rose JD: The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine. 2001, 19: 3076-3090. 10.1016/S0264-410X(01)00044-5.CrossRefPubMed
3.
go back to reference Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, Brownell M, Roos L, De Serres G: Epidemiology of varicella zoster virus infection in Canada and in the United Kingdom. Epidemiol Infect. 2001, 127: 305-314. 10.1017/S0950268801005921.CrossRefPubMedPubMedCentral Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, Brownell M, Roos L, De Serres G: Epidemiology of varicella zoster virus infection in Canada and in the United Kingdom. Epidemiol Infect. 2001, 127: 305-314. 10.1017/S0950268801005921.CrossRefPubMedPubMedCentral
4.
go back to reference Donahue JG, Choo PW, Manson JE, Platt R: The incidence of herpes zoster. Arch Intern Med. 1995, 155: 1605-1609. 10.1001/archinte.155.15.1605.CrossRefPubMed Donahue JG, Choo PW, Manson JE, Platt R: The incidence of herpes zoster. Arch Intern Med. 1995, 155: 1605-1609. 10.1001/archinte.155.15.1605.CrossRefPubMed
5.
go back to reference Levin MJ, Smith JG, Kaufhold RM, Barber D, Hayward AR, Chan CY, Chan IS, Li DJ, Wang W, Keller PM, Shaw A, Silber JL: Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis. 2003, 188: 1336-1344. 10.1086/379048.CrossRefPubMed Levin MJ, Smith JG, Kaufhold RM, Barber D, Hayward AR, Chan CY, Chan IS, Li DJ, Wang W, Keller PM, Shaw A, Silber JL: Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis. 2003, 188: 1336-1344. 10.1086/379048.CrossRefPubMed
6.
go back to reference Gauthier A, Breuer J, Carrington D, Martin M, Remy V: Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect. 2009, 137: 38-47. 10.1017/S0950268808000678.CrossRefPubMed Gauthier A, Breuer J, Carrington D, Martin M, Remy V: Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect. 2009, 137: 38-47. 10.1017/S0950268808000678.CrossRefPubMed
7.
go back to reference Stein AN, Britt H, Harrison C, Conway EL, Cunningham A, MacIntyre CR: Herpes zoster burden of illness and health care resource utilization in the Australian population aged 50 years and older. Vaccine. 2009, 27: 520-529. 10.1016/j.vaccine.2008.11.012.CrossRefPubMed Stein AN, Britt H, Harrison C, Conway EL, Cunningham A, MacIntyre CR: Herpes zoster burden of illness and health care resource utilization in the Australian population aged 50 years and older. Vaccine. 2009, 27: 520-529. 10.1016/j.vaccine.2008.11.012.CrossRefPubMed
8.
go back to reference Yawn BP, Saddier P, Wollan PC, St. Sauver JL, Kurland MJ, Sy LS: A population-based study of the incidence and complication rates of herpes zoster before zoster vaccination introduction. Mayo Clin Proc. 2007, 82: 1341-1349. 10.4065/82.11.1341.CrossRefPubMed Yawn BP, Saddier P, Wollan PC, St. Sauver JL, Kurland MJ, Sy LS: A population-based study of the incidence and complication rates of herpes zoster before zoster vaccination introduction. Mayo Clin Proc. 2007, 82: 1341-1349. 10.4065/82.11.1341.CrossRefPubMed
10.
go back to reference Oster G, Harding G, Dukes E, Edelsberg J, Cleary P: Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain. 2005, 6: 356-363. 10.1016/j.jpain.2005.01.359.CrossRefPubMed Oster G, Harding G, Dukes E, Edelsberg J, Cleary P: Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain. 2005, 6: 356-363. 10.1016/j.jpain.2005.01.359.CrossRefPubMed
11.
go back to reference Katz J, Cooper E, Walther R, Sweeney E, Dworkin R: Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis. 2004, 39: 342-348. 10.1086/421942.CrossRefPubMed Katz J, Cooper E, Walther R, Sweeney E, Dworkin R: Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis. 2004, 39: 342-348. 10.1086/421942.CrossRefPubMed
12.
go back to reference Brisson M, Pellissier JM, Camden S, Quach C, De Wals P: The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccin. 2008, 4: 238-245.CrossRefPubMed Brisson M, Pellissier JM, Camden S, Quach C, De Wals P: The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccin. 2008, 4: 238-245.CrossRefPubMed
13.
go back to reference Schmader KE: Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002, 18: 350-354. 10.1097/00002508-200211000-00002.CrossRefPubMed Schmader KE: Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002, 18: 350-354. 10.1097/00002508-200211000-00002.CrossRefPubMed
14.
go back to reference Schmader KE, Sloane R, Pieper C, Coplan PM, Nikas A, Saddier P, Chan I, Choo P, Levin MJ, Johnson G, Williams HM, Oxman MN: The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain. 2007, 23: 490-496. 10.1097/AJP.0b013e318065b6c9.CrossRefPubMed Schmader KE, Sloane R, Pieper C, Coplan PM, Nikas A, Saddier P, Chan I, Choo P, Levin MJ, Johnson G, Williams HM, Oxman MN: The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain. 2007, 23: 490-496. 10.1097/AJP.0b013e318065b6c9.CrossRefPubMed
15.
go back to reference Volpi A, Gross G, Hercogova J, Johnson RW: Current management of herpes zoster. The European view. Am J Clin Dermatol. 2005, 6: 317-325. 10.2165/00128071-200506050-00005.CrossRefPubMed Volpi A, Gross G, Hercogova J, Johnson RW: Current management of herpes zoster. The European view. Am J Clin Dermatol. 2005, 6: 317-325. 10.2165/00128071-200506050-00005.CrossRefPubMed
16.
go back to reference Johnson RW, Wasner G, Saddier P, Baron R: Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient. Drugs Aging. 2008, 25: 991-1006. 10.2165/0002512-200825120-00002.CrossRefPubMed Johnson RW, Wasner G, Saddier P, Baron R: Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient. Drugs Aging. 2008, 25: 991-1006. 10.2165/0002512-200825120-00002.CrossRefPubMed
18.
go back to reference Di Luzio Paparatti U, Arpinelli F, Visona G: Herpes zoster and its complications in Italy: an observational survey. J Infect. 1999, 38: 116-119. 10.1016/S0163-4453(99)90079-8.CrossRefPubMed Di Luzio Paparatti U, Arpinelli F, Visona G: Herpes zoster and its complications in Italy: an observational survey. J Infect. 1999, 38: 116-119. 10.1016/S0163-4453(99)90079-8.CrossRefPubMed
19.
go back to reference Di Legami V, Gianino MM, Atti MCD, Massari M, Migliardi A, Tomba GS, Zotti C, Zoster Study Group: Epidemiology and costs of herpes zoster: background data to estimate the impact of vaccination. Vaccine. 2007, 25: 7598-7604. 10.1016/j.vaccine.2007.07.049.CrossRefPubMed Di Legami V, Gianino MM, Atti MCD, Massari M, Migliardi A, Tomba GS, Zotti C, Zoster Study Group: Epidemiology and costs of herpes zoster: background data to estimate the impact of vaccination. Vaccine. 2007, 25: 7598-7604. 10.1016/j.vaccine.2007.07.049.CrossRefPubMed
20.
go back to reference Filippi A, Bignamini AA, Sessa E, Samani F, Mazzaglia G: Secondary prevention of stroke in Italy: a cross-sectional survey in family practice. Stroke. 2003, 34: 1010-1014. 10.1161/01.STR.0000062888.90293.AA.CrossRefPubMed Filippi A, Bignamini AA, Sessa E, Samani F, Mazzaglia G: Secondary prevention of stroke in Italy: a cross-sectional survey in family practice. Stroke. 2003, 34: 1010-1014. 10.1161/01.STR.0000062888.90293.AA.CrossRefPubMed
21.
go back to reference Filippi A, Sabatini A, Badioli L, Samani F, Mazzaglia G, Catapano A, Cricelli C: Effects of an automated electronic reminder in changing the antiplatelet drug-prescribing behaviour among General Practitioners in Italy in diabetic patients: an intervention trial. Diabetes Care. 2003, 26: 1497-1500. 10.2337/diacare.26.5.1497.CrossRefPubMed Filippi A, Sabatini A, Badioli L, Samani F, Mazzaglia G, Catapano A, Cricelli C: Effects of an automated electronic reminder in changing the antiplatelet drug-prescribing behaviour among General Practitioners in Italy in diabetic patients: an intervention trial. Diabetes Care. 2003, 26: 1497-1500. 10.2337/diacare.26.5.1497.CrossRefPubMed
23.
go back to reference Leyland AH, Goldstein H: Multilevel Modelling of Health Statistics. 2001, Chichester: Wiley Leyland AH, Goldstein H: Multilevel Modelling of Health Statistics. 2001, Chichester: Wiley
24.
go back to reference Italian Medicines Agency (Agenzia Italiana del Farmaco; AIFA): Prontuario Farmaceutico Nazionale (PFN). Italy. 2005 Italian Medicines Agency (Agenzia Italiana del Farmaco; AIFA): Prontuario Farmaceutico Nazionale (PFN). Italy. 2005
26.
go back to reference Chidiac C, Brucelle J, Daures J-P, Hoang-Xuan T, Morel P, Leplege A, El Hasnaoui A, de Labareyer C: Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis. 2001, 33: 62-69. 10.1086/320884.CrossRefPubMed Chidiac C, Brucelle J, Daures J-P, Hoang-Xuan T, Morel P, Leplege A, El Hasnaoui A, de Labareyer C: Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis. 2001, 33: 62-69. 10.1086/320884.CrossRefPubMed
27.
go back to reference Fleming DM, Cross KW, Cobb WA, Chapman RS: Gender difference in the incidence of shingles. Epidemiol Infect. 2004, 132: 1-5. 10.1017/S0950268803001523.CrossRefPubMedPubMedCentral Fleming DM, Cross KW, Cobb WA, Chapman RS: Gender difference in the incidence of shingles. Epidemiol Infect. 2004, 132: 1-5. 10.1017/S0950268803001523.CrossRefPubMedPubMedCentral
28.
go back to reference Opstelten W, Van Essen GA, Schellevis F, Verheij TJM, Moons KGM: Gender as an independent risk factor for herpes zoster: a population-based prospective study. Ann Epidemiol. 2006, 16: 692-695. 10.1016/j.annepidem.2005.12.002.CrossRefPubMed Opstelten W, Van Essen GA, Schellevis F, Verheij TJM, Moons KGM: Gender as an independent risk factor for herpes zoster: a population-based prospective study. Ann Epidemiol. 2006, 16: 692-695. 10.1016/j.annepidem.2005.12.002.CrossRefPubMed
29.
go back to reference Schmader K, Gorge LK, Burchett BM, Pieper CF, Hamilton JD: Racial differences in the occurrence of herpes zoster. J Infect Dis. 1995, 171: 701-704.CrossRefPubMed Schmader K, Gorge LK, Burchett BM, Pieper CF, Hamilton JD: Racial differences in the occurrence of herpes zoster. J Infect Dis. 1995, 171: 701-704.CrossRefPubMed
30.
go back to reference Gross G, Schöfer H, Wassilew S, Friese K, Timm A, Guthoff R, Pau HW, Malin JP, Wutzler P, Doerr HW: Herpes zoster guideline of the German Dermatology Society (DDG). J Clin Virol. 2003, 26: 277-289. 10.1016/S1386-6532(03)00005-2.CrossRefPubMed Gross G, Schöfer H, Wassilew S, Friese K, Timm A, Guthoff R, Pau HW, Malin JP, Wutzler P, Doerr HW: Herpes zoster guideline of the German Dermatology Society (DDG). J Clin Virol. 2003, 26: 277-289. 10.1016/S1386-6532(03)00005-2.CrossRefPubMed
31.
go back to reference Oxman MN: Clinical manifestations of herpes zoster. Varicella-zoster Virus: Virology and Clinical Management. Edited by: Arvin AM, Gershon AA. 2000, Cambridge, UK: Cambridge University Press, 246-275. full_text.CrossRef Oxman MN: Clinical manifestations of herpes zoster. Varicella-zoster Virus: Virology and Clinical Management. Edited by: Arvin AM, Gershon AA. 2000, Cambridge, UK: Cambridge University Press, 246-275. full_text.CrossRef
32.
go back to reference Chen TM, Gorge S, Woodruff CA, Hsu S: Clinical manifestations of varicella-zoster virus infection. Dermatol Clin. 2002, 20: 267-282. 10.1016/S0733-8635(01)00012-2.CrossRefPubMed Chen TM, Gorge S, Woodruff CA, Hsu S: Clinical manifestations of varicella-zoster virus infection. Dermatol Clin. 2002, 20: 267-282. 10.1016/S0733-8635(01)00012-2.CrossRefPubMed
33.
go back to reference Choo PW, Galil K, Donahue JG, Walker AM, Spiegelman D, Platt R: Risk factors for post herpetic neuralgia. Arch Intern Med. 1997, 157: 1217-1224. 10.1001/archinte.157.11.1217.CrossRefPubMed Choo PW, Galil K, Donahue JG, Walker AM, Spiegelman D, Platt R: Risk factors for post herpetic neuralgia. Arch Intern Med. 1997, 157: 1217-1224. 10.1001/archinte.157.11.1217.CrossRefPubMed
34.
go back to reference Dworkin RH, Boon RJ, Griffin DR, Phung D: Postherpetic neuralgia: impact of famciclovir, age, rash severity and acute pain in herpes zoster patients. J Infect Dis. 1998, 178 (Suppl 1): 76S-80S. 10.1086/514260.CrossRef Dworkin RH, Boon RJ, Griffin DR, Phung D: Postherpetic neuralgia: impact of famciclovir, age, rash severity and acute pain in herpes zoster patients. J Infect Dis. 1998, 178 (Suppl 1): 76S-80S. 10.1086/514260.CrossRef
35.
go back to reference Wood MJ, Kay R, Dworkin RH, Soong SJ, Whitley RJ: Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis. 1996, 22: 341-347.CrossRefPubMed Wood MJ, Kay R, Dworkin RH, Soong SJ, Whitley RJ: Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis. 1996, 22: 341-347.CrossRefPubMed
36.
go back to reference Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Hongyuan Zhang J, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW, Loutit J, Holodniy M, Keitel WA, Crawford GE, Yeh S-S, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan ISF, Wang WWB, Annuziato PW, Silber JL, for the Shingles Prevention Study Group: A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005, 352: 2271-2284. 10.1056/NEJMoa051016.CrossRefPubMed Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Hongyuan Zhang J, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW, Loutit J, Holodniy M, Keitel WA, Crawford GE, Yeh S-S, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan ISF, Wang WWB, Annuziato PW, Silber JL, for the Shingles Prevention Study Group: A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005, 352: 2271-2284. 10.1056/NEJMoa051016.CrossRefPubMed
37.
go back to reference Brisson M, Edmunds WJ: Epidemiology of varicella-zoster virus in England and Wales. J Med Virol. 2003, 70 (Suppl 1): S9-S14. 10.1002/jmv.10313.CrossRefPubMed Brisson M, Edmunds WJ: Epidemiology of varicella-zoster virus in England and Wales. J Med Virol. 2003, 70 (Suppl 1): S9-S14. 10.1002/jmv.10313.CrossRefPubMed
38.
go back to reference Gil A, San-Martin M, Carrasco P, Gonzales A: Epidemiology of severe varicella-zoster virus infection in Spain. Vaccine. 2004, 22: 3947-3951. 10.1016/j.vaccine.2004.04.004.CrossRefPubMed Gil A, San-Martin M, Carrasco P, Gonzales A: Epidemiology of severe varicella-zoster virus infection in Spain. Vaccine. 2004, 22: 3947-3951. 10.1016/j.vaccine.2004.04.004.CrossRefPubMed
39.
go back to reference Scott FT, Johnson RW, Leedham-Green M, Davies E, Edmunds WJ, Breuer J: The burden of herpes zoster: A prospective population based study. Vaccine. 2006, 24: 1308-1314. 10.1016/j.vaccine.2005.09.026.CrossRefPubMed Scott FT, Johnson RW, Leedham-Green M, Davies E, Edmunds WJ, Breuer J: The burden of herpes zoster: A prospective population based study. Vaccine. 2006, 24: 1308-1314. 10.1016/j.vaccine.2005.09.026.CrossRefPubMed
40.
go back to reference Opstelten W, van Essen GA, Mons KGM, van Wijck AJM, Schellevis FG, Kalkman CJ, Verheij TJM: Do herpes zoster patients receive antivirals? A Dutch national survey in general practice. Family Practice. 2005, 22: 523-528. 10.1093/fampra/cmi055.CrossRefPubMed Opstelten W, van Essen GA, Mons KGM, van Wijck AJM, Schellevis FG, Kalkman CJ, Verheij TJM: Do herpes zoster patients receive antivirals? A Dutch national survey in general practice. Family Practice. 2005, 22: 523-528. 10.1093/fampra/cmi055.CrossRefPubMed
41.
go back to reference Wood MJ, Shukla S, Fiddian AP, Crooks RJ: Treatment of acute herpes zoster: effect of early (<48 h) versus late (48-72 h) therapy with acyclovir and valacicolvir on prolonged pain. J Infect Dis. 1998, 178 (Suppl 1): S81-S84. 10.1086/514271.CrossRefPubMed Wood MJ, Shukla S, Fiddian AP, Crooks RJ: Treatment of acute herpes zoster: effect of early (<48 h) versus late (48-72 h) therapy with acyclovir and valacicolvir on prolonged pain. J Infect Dis. 1998, 178 (Suppl 1): S81-S84. 10.1086/514271.CrossRefPubMed
42.
go back to reference Li Q, Chen N, Yang J, Zhou D, Zhang Q, He L: Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2009, 2: CD006866-PubMed Li Q, Chen N, Yang J, Zhou D, Zhang Q, He L: Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2009, 2: CD006866-PubMed
Metadata
Title
Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: A retrospective, population-based study
Authors
Leonardo Emberti Gialloreti
Monica Merito
Patrizio Pezzotti
Luigi Naldi
Antonio Gatti
Maud Beillat
Laurence Serradell
Rafaelle di Marzo
Antonio Volpi
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2010
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-10-230

Other articles of this Issue 1/2010

BMC Infectious Diseases 1/2010 Go to the issue